Outcome of Patients Undergoing Redo Lung Transplantation: Insights from a 15-Year Single-Centre Experience

All articles of this category (opens in new window) Background: Long-term survival following lung transplantation is primarily limited by the development of chronic lung allograft dysfunction (CLAD). Redo lung transplantation (re-LTx) currently represents the only definitive therapeutic option for selected patients with advanced CLAD. This study provides a comprehensive analysis of re-LTx outcomes over a 15-year period at a single high-volume transplant center. Methods: All lung transplant procedures performed between January 2010 and June 2025 were retrospectively reviewed. Patient demographics, perioperative variables, and clinical outcomes were compared between primary and redo lung transplant recipients. The median follow-up was 124 months. Results: A total of 1,707 lung transplants were performed during the study period, of which 1,609 (94.3%) were primary transplants and 98 (5.7%) were redo procedures. Re-LTx recipients were significantly younger than those undergoing primary transplantation (41.0 ± 14.2 vs. 48.2 ± 15.8 years; p < 0.001). The proportion of pediatric recipients (